The study by Rose and Behm in this issue (1) is a remarkable first attempt to improve smoking cessation by selecting treatment for individual patients based on an initial test period. Smoking cessation treatments specify a quit date, usually 2 weeks after the initiation of treatment. Rose and Behm used this 2-week period to identify those patients who would likely respond to nicotine replacement therapy, the simplest and safest treatment. The test was to identify those patients who decreased their smoking by 50% during open-label treatment with a nicotine transdermal patch. Most patients received one 21-mg patch daily, but heavier smokers received two patches. The one-third of patients who decreased their cigarette consumption by 50% or more then continued on the patch for 12 weeks. Half these patients remained abstinent at 12 weeks, and 22% remained abstinent at 6 months. The favorable prognosis for patients who immediately decreased smoking with nicotine patch treatment replicates earlier findings from Rose and colleagues (2).
because of the multiple interventions, but it effectively used the 600 patients enrolled to answer questions as clinicians would address them: Does the simplest, safest treatment, nicotine patch, work for a given patient? If not, what additions (bupropion) or changes (varenicline) are likely to help? The answer is that nicotine patch alone works for half the patients, and the addition of bupropion will rescue about 20% of the remaining half. Over 6 months, only about 15%220% of patients stop smoking with any of the three treatments. The nicotine patch challenge is a useful way to direct more effective treatment to those patients who show early on that they need it.
Although many patients in this study were helped, most had returned to smoking at 6 months, which points out the recalcitrance of this addiction to remediation. Public policy to discourage or prohibit smoking has been helpful, but the mass marketing of cigarettes and their continued adoption by young smokers, who are those most vulnerable to longer-term addiction, is problematic (3). Patients with psychiatric disorders other than obsessive-compulsive disorder, ADHD, and anxiety disorders were excluded, despite the fact that psychotic, depressed, and alcohol-abusing patients have much higher smoking rates and cigarette consumption than any other group (4). Rose and Behm speculate on whether the overall rate of response at 6 months suggests that longer-term treatments with multiple agents might be more effective for all patients, but studies have not yet addressed this question. More effective treatment is needed for the many patients who relapse in the course of the first 3 months of treatment.
In the search for new treatments, it is also worthwhile to consider what brain mechanisms might underlie the difference in response between patients. Nicotine, like most drugs of abuse, hijacks neuronal receptors in the brain. A family of nearly a dozen nicotinic acetylcholine receptors, which normally respond to acetylcholine, are the mechanism used by nicotine to maintain addiction. Genetic variation in the expression and function of these nicotinic receptors is known to be a significant determinant of the liability to nicotine addiction and the response to nicotine replacement therapy (4, 5) . It is possible that the Rose and Behm test, simple enough to be applied in any clinical treatment setting, identifies some of this genetic variation. If that is the case, then this clinical insight might also help identify which genetic variants are the most treatment resistant and might be the targets of additional treatment development.
